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Campus compounding pharmacies play an important role in public health. Herpes simplex is one of the most common viral 
diseases in humans, which generates a great demand for acyclovir capsules in compounding pharmacy. It is well known 
that the formulation's components influence the effectiveness of the drug. The objective of this study is to show the 
applicability of Box-Behnken design in optimization of a compounded formulation and to evaluate the effect of excipients 
on dissolution and drug content in acyclovir 200 mg capsules produced at UFF´s University Pharmacy (FAU). The 
formulations were prepared and evaluated for average weight test, uniformity of dosage units and in vitro dissolution, while 
meeting pharmacopoeial specifications. A statistical analysis showed that sodium starch glycolate, Aerosil®, influences 
drug content and dissolution results. Magnesium stearate shows no influence on the dissolution at different concentrations 
but influences the assay results. A numerical optimization was applied to adjust the formulation variables based on the 
foresaid responses, accomplishing the best formulation that will be prepared and dispensed at FAU upon medical 
prescription. 
 





Campus compounding pharmacies are important sources 
of medicines at low cost and individualized therapy, 
always ensuring the quality of the products dispensed.   
The current legislation for compounding pharmacies (1) 
requires, as far as capsules quality control test is 
concerned, weight determination, standard deviation, and 
relative standard deviation. These analyses establish 
whether there was a uniform distribution of the powder 
mixture in the analyzed batch. On the other hand, they do 
not provide any information on the homogeneity of the 
encapsulated powder mixture. Therefore, it is feasible that 
a particular formulation meets the pharmacopeial 
acceptance criteria for the average weight and, at the same 
time, falls on non-conformity for the content uniformity 
test and in vitro dissolution test, which are important 
parameters for quality assessment of oral solid dosage 
form (2). 
Process or formulation variables could impact the 
medicine quality, the optimization of these parameters 
could be carried out using the Design of Experiments 
(DoE) approach. 
DoE is a part of quality by design and can be used to 
generate design space, which determines the 
multidimensional combination and interaction of 
independent variables that have been demonstrated to 
provide a product of desired quality (3). The Box-Behken 
technique is capable of analyzing different variables and 
of helping to select the optimal composition with 
minimum number of experiments, saving time and 
resources (3, 4).  
The University Pharmacy of Fluminense Federal University 
(FAU), founded in 1996, has a respectful track record in 
compounding pharmacy including the production of liquid, 
semi-solid dosage forms and capsules. Currently, it has been 
reformulating its products to optimize quality parameters, 
including acyclovir capsules. 
Acyclovir (Figure 1) is an antiviral drug that is primarily 
used for the treatment of Herpes simplex virus (HSV) as 
well as infections due to Varicella zoster and Herpes zoster 
virus. It is a guanosine analogue with a functional aliphatic 
group that is present in the side chain responsible for 
stopping the virus replication process and competitively 
inhibiting the viral DNA synthesis. Due to its potent 
selectivity, it is currently the antiviral of choice for the 
treatment of the different forms of herpetic infection 
produced by HSV-1 and HSV-2 (5).  
The available dosage forms of acyclovir are capsules, 
tablets, suspension, and topical ointment (6) being included 
on the World Health Organization’s (WHO) list of essential 
medicines needed in basic health system (7). The demand 
for acyclovir capsules in the FAU has been increasing since 
the compounding allows the supply of medicines in 
individualized formulations at a lower cost (8). The present 
work aimed to optimize the FAU’s acyclovir formulation 
based in DoE and considering the effect of excipients on 
pharmacopeial quality. Furthermore, to show the 
applicability of Box-Behnken design in the development of 
formulations in compounding pharmacies, taking advantage 
of its reduced number of experiments. 
 
 




Figure 1. Molecular structure of acyclovir. 
 
Experimental section  
 
Chemicals and reagents 
 
Acyclovir (Fragon, Brazil), colloidal silicon dioxide – 
Aerosil® (Farmos, Brazil), magnesium stearate (Farmos, 
Brazil), sodium starch glycolate (Blanver, Brazil), 
microcrystalline cellulose (Galena, Brazil), sodium 
hydroxide (Vetec, Brazil), hydrochloric acid (Proquimos, 
Brazil), acetic acid (Synth, Brazil). Deionized water was 
obtained from the water deionizer Gehaka model 0510LX 
(Gehaka, São Paulo – 96 Brazil). 
 
Experimental design  
 
A Box–Behnken factorial design with three variables in 
three levels was used to study, to optimize, and to evaluate 
the main effects, namely, interaction, and quadratic 
effects of the selected independent variables on the 
response variables.  
The Box–Behnken was carried out in Statistica 12.5 
Software to evaluate the effects of the independent 
variables on the in vitro dissolution test and assay of 200 
mg acyclovir capsules. All the experimental tests were 
carried out at the University Laboratory Rodolpho Albino 
(LURA / UFF). 
Selection of excipients and their amounts was based on 
FAU´s original formulation of 200 mg acyclovir capsules, 
composed of Aerosil® (0.5%) and magnesium stearate 
(1%). Sodium starch glycolate was chosen as a 
disintegrating agent and it is commonly used in 
concentrations between 2% and 8%, with the optimum 
concentration about 4% in oral solid dosage forms (9). 
The independent variables studied were the excipients in 
different concentrations: A) Aerosil®, B) magnesium 
stearate, C) sodium starch glycolate. Each independent 
variable level was expressed by (−1) for the low level, (0) 
for the medium and (1) for the high level as shown in 
Table 1. The influence of each excipient in the 
formulation’s performance was evaluated using the 
absence of each one in the low level (-1). Table 2 presents 
the matrix factorial design that includes 15 formulations. 
Formulation 7 is the original formula, and the central 
point was made in triplicate. The effect of the variables on 
the acyclovir dissolution and assay were studied (response 
variable). 




Level / % p/p 
Low (-1) Middle (0) High (+1) 
Sodium starch 
glycolate 
0 4 8 
Aerosil® 0 0.5 1 
Magnesium 
stearate 
0 0.5 1 
 
Table 2. Matrix factorial design of acyclovir capsules. 








1 0 0 0.5 
2 8 0 0.5 
3 0 1 0.5 
4 8 1 0.5 
5 0 0.5 0 
6 8 0.5 0 
7 0 0.5 1 
8 8 0.5 1 
9 4 0 0 
10 4 1 0 
11 4 0 1 
12 4 1 1 
13 4 0.5 0.5 
14 4 0.5 0.5 
15 4 0.5 0.5 
 
Each formulation contained acyclovir 0.1992g (equivalent 
to 0.2 g of acyclovir) and the excipient quantitative 
composition was described in Table 2. Microcrystalline 
cellulose was used as a diluent in quantum satis (q.s.) to 
complete each capsule volume, with values corresponding 
from 45,21 to 55,39% of the concentration (w/w), 
depending on the formulation. The powder mixtures were 
prepared by manually mixing in geometric dilution, then 
filled into size 00 capsules (10). A total of sixty (60) 
capsules were obtained in each experiment. 
The response variables used for optimization of the 
formulation were average weight, acyclovir content and 
amount dissolved at 45 minutes from dissolution test. 
The results were expressed as mean ± standard deviation 
(SD) using Microsoft Excel software (Redmond, WA, 
USA). The statistical analysis was performed by analysis of 
variance (ANOVA) using Statistica 12.5 Software, and the 
results were compared graphically by Pareto chart of 
standardized effects and by 3D response surface plot 
generated by the software. Significance level was 




The weight determination was carried out by using 20 units, 
according to Brazilian Pharmacopoeia 6th edition (11) 
method. The average weight was calculated by comparing 
the difference between full and empty capsules. The 
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uniformity of weight was evaluated based on variation 
limits for the average weights present in the Brazilian 
Pharmacopeia. The standard deviation and relative 
standard deviation were calculated. It was considered 




The concentration of acyclovir was determined by UV 
spectrophotometry (Perkin Elmer, Model: Lambda 35 
UV/VIS Spectrometer) following the method uniformity 
of dosage units by weight variation, as described in 
Brazilian Pharmacopeia 6th edition (12). Twenty 
individual capsules were accurately weighed (Shimadzu, 
Model: AUY220) before and after removing their content, 
then the average weight was recorded. The content of the 
capsules were triturated by using mortar and pestle where 
the equivalent of 0.1 g of acyclovir was transferred to a 
100 mL volumetric flask. Then, 60 mL of a sodium 
hydroxide 0.1 M solution was added and put into 
sonication for 15 minutes without heating. Thereafter, the 
flask was completed with 0.1 M NaOH, homogenized and 
filtered. Then 15 mL of this solution was transferred to a 
100 mL volumetric flask, adding 5.8 mL 2 M 
hydrochloric acid and 50 mL deionized water, 
homogenized and the flask was filled with deionized 
water. Subsequently, 5 mL was transferred to a 50 mL 
volumetric flask and filled with acetic acid 0.1 M. The 
absorbance at 255 nm was determined using 0.1 N 
hydrochloric acid as blank. A calibration curve, ranging 
from 5 to 18 μg/ml, was constructed by the absorbances 
at 255 nm using 0.1 N hydrochloric acid as solvent (y = 




The dissolution tests were carried out in a dissolution 
tester (Nova Etica, Model 299) according to the acyclovir 
capsules monograph of U.S. Pharmacopoeia (USP) (13): 
apparatus 1 (basket), speed of 100 rpm, 900 mL of 0.1 N 
hydrochloric acid solution at 37 ± 0.5oC. The filtered 
aliquots of 1 mL were removed from each vessel at 45 
minutes, transferred to 10 mL volumetric flask and filled 
with 0.1 N hydrochloric acid.  
The absorbance at 254 nm was determined by UV 
spectrophotometry (Perkin Elmer, Model: Lambda 35 
UV/VIS Spectrometer) using 0.1 N hydrochloric acid as 
blank. USP (13) recommends not less than 75% of 
acyclovir dissolved in 45 minutes of test. The same 
calibration curve described in acyclovir content section 
was used.  
The dissolution results obtained were the variables of the 
experimental planning and were analyzed in Statistica 




Optimization of formulation using desirability approach 
 
In Statistica 12.5 Software, numerical optimization was 
applied to optimize the formulation variables based on the 
aforesaid responses.  
Three formulations were prepared using the predicted 
values and desirability for the dissolution (FA), acyclovir 
content (FB) and the original FAU´s formulation (FC). The 
dissolution profile was determined for each formulation, for 
this test it was used the same conditions and method 
described above (13), but 1 mL were removed from each 
vessel at 5, 10, 15, 20, 30, 45 and 60 minutes, with 
immediate replacement of fresh medium to keep the balance 
of the sink condition (14). Thereafter, the samples were 
filtered, and the percentages of drug dissolved were 
determined in a UV spectrophotometer (Perkin Elmer, 
Model: Lambda 35 UV/VIS Spectrometer) at 254 nm using 
0.1 N hydrochloric acid as blank. The dissolution profiles 
were obtained. The same calibration curve described in 
acyclovir content section was used. 
The dissolution efficiencies (DE%) were determined for the 
ratio among the area under the dissolution curves, between 
the times zero and 60 minutes (AUC0-60) calculated applying 
the trapezoidal method, and the total area of the rectangle 
(AUCTR) defined for the ordinate (100% of dissolution) and 
for the abscissa (t=60 minutes) (15). The statistical analysis 
of variance (ANOVA) followed Tukey's post-hoc test, using 
Statistica 12.5 software, was performed considering as 
significant the values of p < 0.05. 
 
Results and Discussion 
 
All formulations met the requirements for average weight 
according to the (limit variation of 7.5%) preconized by 
Brazilian Pharmacopoeia 6th edition (11) and showed low 
relative standard deviation (RSD) values, between 1.35-
3.58% (Table 3). 
 
Influence of independent variables on the acyclovir 
content 
 
The 15 formulations proposed in experiment design 
presented results of drug content ranging between 89.94-
100.5% (Table 4). 
The results of acyclovir content were loaded in Statistica 
12.5 Software. Figure 2 illustrates the interplay between 
different factors studied for their effect on acyclovir content. 
The results were present as the response at different 
combinations of two variables, keeping the third variable at 
its middle level.  
The three-dimensional response surface curves demonstrate 
that magnesium stearate shows a positive influence in 
intermediate concentration, while Aerosil® and sodium 
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Table 3. Average weight of the developed formulations (1-15). 
Formula
tion 
Average weight (g) 
X ± S (RSD%) 






























































































X = average, S = standard deviation, RSD = relative standard 
deviation, Max value = maximum value of weight; Min value = 
minimum value of weight (n=20), SL = superior weight 
variation limit, IL = inferior weight variation limit. 
 
Table 4. Acyclovir content of the developed formulations (1-15) 
Formulation Acyclovir content (%) 
X ± S (RSD%) 
1 98.68 ± 0.62 (0.63%) 
2 98.13 ± 1.27 (1.29%) 
3 97.17 ± 8.00 (8.24%) 
4 100.5 ± 1.81 (1.79%) 
5 96.65 ± 3.10 (3.21%) 
6 92.91 ± 2.23 (2.40%) 
7 93.26 ± 3.44 (3.69%) 
8 91.97 ± 2.36 (2.57%) 
9 92.72 ± 2.76 (2.97%) 
10 92.18 ± 3.46 (3.75%) 
11 89.94 ± 4.44 (4.94%) 
12 90.53 ± 4.03 (4.46%) 
13 90.17 ± 3.79 (4.21%) 
14 91.02 ± 4.85 (5.32%) 
15 91.32 ± 3.22 (3.53%) 
X = average, S = standard deviation, RSD = relative standard 
deviation. 
 
Pareto charts were plotted to represent ANOVA tests and 
determine the effect of the independent variables, their 
interactions, and their quadratic effects on the dependent 
variables. Positive (+) and negative (–) coefficients show 
the synergistic effect and the antagonistic effect, 
respectively (14). Pareto chart (Figure 3) corroborate that 
sodium starch glycolate and Aerosil® have a negative 
quadratic influence on the assay, while magnesium stearate 
has a quadratic and linear influence on the result, with p-
values lower than 0.05 (Figure 3).  
 
 
Figure 2. Response surface plots showing the effect of the three 
variables on the acyclovir content: (a) the effect of magnesium 
stearate and Aerosil®; (b) the effect of Aerosil® and sodium starch 
glycolate; (c) the effect of magnesium stearate and sodium starch 




Figure 3. Pareto chart of standardized effects for acyclovir content. 
MS = magnesium stearate, SSG = sodium starch glycolate, Q = 
quadratic, L = Linear. 
 
Influence of independent variables on the dissolution test 
 
All formulations met the requirements for dissolution test of 
USP 44 (13), where not less than 75% was dissolved in 45 
minutes of testing, with values between 83-91% of acyclovir 
dissolved in 45 min (Table 5). 
The data from the 15 formulations (Table 5) were analyzed 
in the Statistica 12.5 Software. Figure 4 illustrates the 
interplay between the variables studied and their effect on 
acyclovir dissolution. The three-dimensional response 
surface curves demonstrate that magnesium stearate show 
no influence on the dissolution at different concentrations, 
while sodium starch glycolate at medium concentration and 
Aerosil® at higher concentration displayed higher 
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Table 5. Percentages of acyclovir dissolved for the developed 
formulations (1-15). 
Formulation Acyclovir dissolved (%) 
X ± S (RSD%) 
1 90.57 ± 0.028 (3.07 %) 
2 89.37 ± 0.033 (3.66%) 
3 90.98 ± 0.032 (3.55 %) 
4 88.51 ± 0.021 (2.39 %) 
5 88.66 ± 0.020 (2.29 %) 
6 89.21 ± 0.033 (3.70 %) 
7 89.01 ± 0.046 (5.14 %) 
8 88.58 ± 0.011 (1.26 %) 
9 90.69 ± 0.040 (4.45 %) 
10 90.42 ± 0.017 (1.84 %) 
11 88.99 ± 0.023 (2.62 %) 
12 91.50 ± 0.023 (2.56 %) 
13 90.87 ± 0.025 (2.75 %) 
14 91.05 ± 0.027 (2.91 %) 
15 91.04 ± 0.025 (2.76 %) 




Figure 4. Response surface plots showing the effect of the three 
variables on the acyclovir dissolved: (a) the effect of Aerosil and 
sodium starch glycolate; (b) the effect of magnesium stearate 
and sodium starch glycolate; (c) the effect of Aerosil® and 
magnesium stearate. MS = magnesium stearate, SSG = sodium 
starch glycolate. 
 
Figure 5 shows ANOVA tests represented by Pareto chart 
and corroborates that sodium starch glycolate generates a 
statistically significant influence on the percentage of 
dissolved acyclovir (p-value < 0.05), influencing the 
dissolution in a quadratic way through the interaction with 
the other excipients of the formulation.  
DoE has been widely used in the pharmaceutical industry 
for research and development of formulations. The 
statistical design for empirical experiments leads to more 
reliable results, saving time and reduction of number 
repetitions of the experiments. The response surface 
methodology studies the relationship between the 
response and their effective factors where regression 
models are used for analyzing the response. The 
experiments in this methodology study the effects of 
various factors and evaluate obtaining the optimal 
conditions to achieve the desired response. The most 
common model of this method is Box–Behnken, that is a 
spherical design and is also utilized for the optimization 
(14). 
Previous works have demonstrated the applicability of Box-
Behnken design to observe the excipients' effect on 
formulation. Dayal et al. (2005) (16) studied the effect of 
excipients on properties of nasal drug delivery system 
hydroyiureia- contains. Using Box-Behnken experimental 
design, it was possible to predict and to indentify the major 
excipients that influences product quality. 
In other study, the experimental design was used to optimize 
and evaluate of excipients (crosslinked caboxymethyl 
cellulose, sodium starch glycolate and starch) on 
domperidone maleate release from tablets, considering the 
main, interaction and quadratic effects. After statistical 
analyses it was observed the increase of dissolution using 
the combination of carboxymethyl cellulose and sodium 
starch glycolate (17).  
In the same way, in development of fast dissolving tablets, 
the Box-Benken design allow to predict an optimal 
formulation, considering excipients kinds and 




Figure 5. Pareto chart of standardized effects for acyclovir 
dissolved. MS = magnesium stearate, SSG = sodium starch 
glycolate, Q = quadratic, L = Linear. 
 
Optimization of formulation using desirability approach 
 
The purpose of the optimization step is to determine the 
ideal level of each independent variable to prepare a product 
with the best quality attributes (3). In the present study, the 
main desirable outcome is to provide an acyclovir 
formulation with the best dissolution profile. In Statistica 
12.5 Software, numerical optimization was applied to 
improve the formulation variables based on the aforesaid 
responses.  
Figure 6 demonstrates that the highest value of desirability 
for the acyclovir content (0.99145) could be achieved at low 
level (-1) of sodium starch glycolate (0%), higher level (+1) 








Figure 6. Graphical representation of predicted and desirability 
values profile for acyclovir content. MS = magnesium stearate, 
SSG = sodium starch glycolate. 
 
Figure 7 demonstrates that the highest value of 
desirability for the acyclovir dissolution (0.95906) could 
be attained at medium level (-0.2) of sodium starch 
glycolate (3.2%), higher level (+1) of Aerosil® (1%) and 
medium level (+0.4) of magnesium stearate (0.7%). 
 
 
Figure 7. Graphical representation of predicted and desirability 
values profiles for acyclovir dissolution. MS = magnesium 
stearate, SSG = sodium starch glycolate. 
 
The theoretical formulations for dissolution (FA), 
acyclovir content (FB) and the original formulation (FC) 
(Table 6) were prepared, and the dissolution profile 
determined. As described in a previous section, the 
microcrystalline cellulose was applied as q.s. acting as a 
diluent in each formulation.  
 




FA FB FC 






SSG 3.2 - - 
Aerosil 1 1 0.5 
MS 0.7 0.4 1 
MC 45.48 48.5 50.25 
MS = magnesium stearate, SSG = sodium starch glycolate; MC = 
microcrystalline cellulose. 
 
Acyclovir is one of the most important antiviral drugs but 
has several problems due to its physical properties (19). The 
oral bioavailability of acyclovir is about 20% with an 
elimination half-life of 1–2 h. The drug has a narrow 
absorption window and is primarily absorbed from the 
region of stomach and upper portion of the small intestine 
(4). Solubility, permeability, and drug product dissolution 
determine the rate and extent of drug absorption from 
immediate-release solid oral dosage forms, such as tablets 
and capsules (20). 
The dissolution performance is one of the most relevant 
parameters in a formulation evaluation as it governs the 
release rate of the drug from the solid form and hence its 
bioavailability (3). 
The dissolution study refers to the evaluation of the position 
change of the solute molecule from its original and 
interacting environment, to a liquid environment with 
different molecules, providing information on the drug's in 
vivo behavior, since the absorption speed is linked to the 
dissolution process, reflecting its characteristics of quality 
and bioavailability (21). 
Several factors can influence these characteristics, including 
the choice of excipients such as lubricants and disintegrants 
that will provide the formulation with good fluidity and 
uniform sizing, as well as allowing adequate conditions for 
the drug to dissolve, respectively (22). In this sense the 
excipients study is particularly important, since their choice 
can change both positively and negatively, as an example, 
the high hydrophobicity of one of these excipients leads to 
difficulty in wetting and reducing its dissolution rate. 
They also influence the handling process, considering the 
mixing operations, the care with previously mixed powders 
so that they do not suffer segregation during their handling, 
and the flow of the powder into the capsules and their 
leveling, processes that can change the uniformity of the 
final product (23). 
The dissolution test was carried out to evaluate and compare 
the release profiles of acyclovir from different formulations 
FA, FB and FC (Table 6). The dissolution profiles of each 
formulation are summarized in Figure 8. Similar results 








Figure 8. Acyclovir formulations dissolution profile in 
formulations (FA), (FB) and (FC). 
 
The dissolution efficiency (DE) can be used to compare 
the dissolution profiles. The results of DE confirm the 
profiles graphical analysis (Figure 8) and the values 
(Table 7). The results were compared using ANOVA 
followed by Tukey's post-hoc test and indicates that there 
are no differences between the dissolution profiles of the 
3 formulations.  
The requirements for dissolution test is not less than 75% 
of acyclovir dissolved in 45 minutes of testing (13), in this 
study more than 75% of acyclovir was released within 5 
min for formulations A, B and C (Table 8). 
 
Table 7. DE values (%) of acyclovir formulations (FA), (FB) 
and (FC). 
Formulation DE (%) 
X ± S (RSD%) 
A 68.29 ± 1.62 (2.37 %) 
B 72.08 ± 1.02 (1.41 %) 
C 69.86 ± 2.77 (3.96 %) 
X = average, S = standard deviation, RSD = relative standard 
deviation. 
 
Table 8. Quantity dissolved (Q) of acyclovir in formulations 
(FA), (FB) and (FC) at 5 and 10 minutes (n=3). 
Formulation Q 5min (%) 
X ± S (RSD%) 
Q 10min (%) 
X ± S (RSD%) 
A 79.52a ± 0.60 (0.76%) 97.95a ± 3.75 (3.82%) 
B 92.77b ± 2.27 (2.45%) 101.39a ± 2.26 (2.33%) 
C 88.68b ± 5.54 (6.24 %) 102.29a ± 4.59 (4.49 %) 
a, b = Same letters in the same column do not show statistically 
significant differences according to ANOVA and Tukey's post-
hoc test. 
 
Rapid dissolution requires >85% of active ingredients be 
dissolved in 30 min (20). More than 97% of acyclovir was 
dissolved from formulations A, B and C within 10 min, 
indicating rapid dissolution (Table 8). If dissolution is 
very rapid, the limiting step for oral absorption would be 
intestinal membrane permeation or gastric emptying, and 
not drug dissolution (20). 
Vaithianathan et al. (2016) (20) studied the influence of 
14 common excipients in cimetidine and acyclovir 
capsules. The quantities were higher than those used in 
typical immediate-release solid oral dosage forms. The 
dissolution profile and a human pharmacokinetic study 
was conducted. Through three four-way crossover BE 
studies, 12 common excipients were found to not impact 
BCS class III drug absorption in humans: sodium lauryl 
sulfate, corn starch, sodium starch glycolate, colloidal 
silicon dioxide, dibasic calcium phosphate, crospovidone, 
lactose, povidone, stearic acid, pregelatinized starch, 
croscarmellose sodium, and magnesium stearate.  
Although formulation A contained 3.2% sodium starch 
glycolate it showed a theoretical influence on the dissolution 
of acyclovir (Figure 5), but there was no statistically 
significant difference in the dissolution profile (Figure 8), 
DE (Table 7) and in the dissolution in times 5 and 10 
minutes (Table 8). Therefore, the addition of this excipient 
is not necessary in the proposed formulation. 
Over-mixing of magnesium stearate is known to slow the 
dissolution by forming a coating around drug and other 
excipients dissolution and possibly reduce drug absorption 
(20). Although formulation C contains 1% magnesium 
stearate, the dissolution profile did not show any statistically 
significant difference (Table 7) compared to formulation A 
and B which contain 0.7% and 0.4% magnesium stearate, 
respectively.  
The three formulations also showed no statistically 
significant difference at times 5 and 10 of dissolution (Table 
8), showing that this variation from 0.4 to 1% of magnesium 
stearate did not impact the dissolution of acyclovir. This 
corroborates what has been shown in the three-dimensional 
response surface curves (Figure 4) and Pareto chart (Figure 
5) that demonstrate that magnesium stearate shows no 
influence on the dissolution at different concentrations. 
The variation of 0.5 to 1% of colloidal silicon dioxide 
(Aerosil®) also did not seem to affect the dissolution rate as 
shown in tables 7, 8 and figure 8, which was also shown in 
figures 4 and 5.  
The theoretical formulations were tested for acyclovir 
content. USP 44 (13) recommends for acyclovir capsules 
not less than 93% of the labeled amount of acyclovir. Only 
on FB, the theoretical formulation for acyclovir content 
achieved this minimum result (Table 9). The uniformity of 
dosage units by weight variation was calculated according 
to Brazilian Pharmacopoeia (11) and FB achieved the lower 
acceptance value (7.96) meeting the requirements (AV < 
15). This formulation was predicted by the software to be 
the formulation that would have the best results for 
acyclovir content and was chosen as the optimized 
formulation to be produced in FAU. 
 
Table 9. Results of acyclovir content for formulations (FA), (FB) 
and (FC). 
Formulation Acyclovir content (%) 
X ± S (RSD%) 
A 92.02 ± 2.38 (2.58 %) 
B 94.44 ± 0.22 (0.24 %) 
C 88.07 ± 1.54 (1.75 %) 





The technique Design of Experiments (DoE) is an excellent 
tool for evaluating the influence of several parameters 
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affecting the formulation at low cost and with small 
number of experiments. By employing this method, it was 
possible to evaluate the influence of the excipients on 
acyclovir 200 mg formulations, and the applicability and 
robustness of the method was demonstrated by the 
software prediction of which formulation would generate 
the best acyclovir content in the capsules, allowing the 
University Pharmacy (FAU) to offer a pharmaceutical 
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